PMC6348774_01
Prepazopanib magnetic resonance imaging suggestive of bulky disease
SAJC-8-51-g001.jpg
PMC6348774_01_SAJC-8-51-g001.jpg
F1
Response assessment MRI [Figure 1] at the end of 3 months of therapy showed significant interval increase in the size and extent of the endoluminal component, while the exoluminal nodular component shows a mild increase in size.
Postpazopanib magnetic resonance imaging suggestive of significant response
SAJC-8-51-g002.jpg
PMC6348774_01_SAJC-8-51-g002.jpg
F2
Post 3 months of pazopanib treatment, MRI [Figure 2] suggested lobulated mass, 3.0 cm away from the anal verge, and as compared to the previous scan, there was a significant decrease in the size of the mass.